Safety of long-term nucleos(t)ide treatment in chronic hepatitis B

Bibliography

• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
   PubMed Web of Science ®Google Scholar
• Gish RG, Lok AS, Chang TT, Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Marcellin P, Buti M, Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-43
   PubMed Web of Science ®Google Scholar
• Manns MP, Akarca US, Chang TT, Low rates of nucleos(t)ide-associated adverse events over long-term treatment with entecavir for chronic hepatitis B. Expert Opin Drug Saf 2012;11:1-8
   PubMedGoogle Scholar
• Lange CM, Bojunga J, Hofmann WP, Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-6
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Soffredini R, Maintained long-term suppression of HBV replication in NUC-naive patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicenter experience. Hepatology 2010;52(Suppl 1):S514A
   Google Scholar
• Ridruejo E, Adrover R, Cocozzella D, Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int J Clin Pract 2011;65:866-70
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
   PubMed Web of Science ®Google Scholar
• Marcellin P, Buti M, Krastev Z, Continued efficacy and safety through 4 years of tenofovir disoproxil fumurate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102): preliminary analysis (abstract). Hepatology 2010;52(Suppl 1):555A
   Google Scholar
• Marcellin P, Buti M, Gane EJ, Five years of Treatment with Tenofovir DF (TDF) for Chronic Hepatitis B (CHB) Infection is Associated with Sustained Viral Suppression and Significant Regression of Histological Fibrosis and Cirrhosis [abstract 1375]. 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011); 4 – 8 November 2011; San Francisco
   Google Scholar
• Gill U, Al-Shamma S, Burke KB, Bone mineral density loss in tenofovir treated chronic hepatitis B virus (HBV) patients is a consequence of vitamin D deficiency and not tenofovir therapy [abstract 1376]. 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011); 4 – 8 November 2011; San Francisco
   Google Scholar
• Lampertico P, Soffredini R, Vigan M, 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice [abstract 1433]. 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011); 4 – 8 November 2011; San Francisco
   Google Scholar
• Petersen J, Ratziu V, Buti M, Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. J Hepatol; In press J Hepatol 2012;56:520-6
   PubMed Web of Science ®Google Scholar
• Lok AS, Trinh HN, Carosi G, Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naive patients with chronic hepatitis B (CHB): the BE-LOW study [abstract 223]. 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011); 4 – 8 November 2011; San Francisco
   Google Scholar
• Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91-100
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sheen IS, Lee CM, Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72
   PubMed Web of Science ®Google Scholar